Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome
Abstract Background No-reflow occurs in 3–4% of all percutaneous coronary interventions (PCIs) and has a strong negative impact on clinical outcomes of acute coronary syndrome (ACS). Therefore, the discovery of a biomarker that can early predict the occurrence of no-reflow has great clinical signifi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-10-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12872-020-01717-5 |
| _version_ | 1819226957975388160 |
|---|---|
| author | Nian-Peng Song Xiao-Wen Zhen Liu-dong Li Lin Zhong Hua Wang Yi An |
| author_facet | Nian-Peng Song Xiao-Wen Zhen Liu-dong Li Lin Zhong Hua Wang Yi An |
| author_sort | Nian-Peng Song |
| collection | DOAJ |
| description | Abstract Background No-reflow occurs in 3–4% of all percutaneous coronary interventions (PCIs) and has a strong negative impact on clinical outcomes of acute coronary syndrome (ACS). Therefore, the discovery of a biomarker that can early predict the occurrence of no-reflow has great clinical significance. Multiple factors including platelet activation are relevant to no-reflow. Calprotectin is found to be a biomarker of plaque instability and is identified to be a novel diagnostic and prognostic biomarker of cardiovascular diseases. The association of plasma calprotectin with platelet activation and no-reflow phenomenon in ACS is not clear. Methods In this prospective study performed at Yantai Yuhuangding Hospital from 2017 to 2018, a total of 176 Chinese patients with ACS who had undergone PCIs were recruited consecutively, aged from 30 to 88 years. Angiographic no-reflow was defined as thrombolysis in myocardial infarction grade less than 3. Blood samples were collected immediately at admission for the detection of plasma calprotectin and platelet–monocyte aggregates formation. Statistical analysis was performed for the variable’s comparisons between groups and the prediction value of plasma calprotectin for no-reflow. Results The mean age of the 176 included ACS patients were 64(±11) years and acute ST-segment elevation myocardial infarction (STEMI) was present in 41.5% of patients. Twenty-two patients had no-reflow during the PCI procedures and the prevalence was 12.5%. Patients with higher plasma calprotectin had a higher level of platelet–monocyte aggregates (PMA) and a higher prevalence of no-reflow (p < 0.001). The multivariate regression showed that plasma calprotectin and admission hs-cTnI were independently associated with PMA, while plasma calprotectin and serum LDL-c were independent predictors of no-reflow (p < 0.001 and p = 0.017). AUC of calprotectin for predicting no-reflow were 0.898. The cut-off value of plasma calprotectin for no-reflow was 4748.77 ng/mL with a sensitivity of 0.95 and a specificity of 0.77. Conclusion Plasma calprotectin was associated with platelet activation and may act as an early predictive biomarker of no-reflow in patients with acute coronary syndrome. |
| first_indexed | 2024-12-23T10:33:45Z |
| format | Article |
| id | doaj.art-2b941ca0a0ed4275b0edacefa97488ad |
| institution | Directory Open Access Journal |
| issn | 1471-2261 |
| language | English |
| last_indexed | 2024-12-23T10:33:45Z |
| publishDate | 2020-10-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj.art-2b941ca0a0ed4275b0edacefa97488ad2022-12-21T17:50:21ZengBMCBMC Cardiovascular Disorders1471-22612020-10-0120111010.1186/s12872-020-01717-5Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndromeNian-Peng Song0Xiao-Wen Zhen1Liu-dong Li2Lin Zhong3Hua Wang4Yi An5Affiliated Hospital of Qingdao University, Qingdao UniversityDepartment of Diagnostics, BinZhou Medical UniversityDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Qingdao UniversityDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Qingdao UniversityDepartment of Cardiology, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Qingdao UniversityAffiliated Hospital of Qingdao University, Qingdao UniversityAbstract Background No-reflow occurs in 3–4% of all percutaneous coronary interventions (PCIs) and has a strong negative impact on clinical outcomes of acute coronary syndrome (ACS). Therefore, the discovery of a biomarker that can early predict the occurrence of no-reflow has great clinical significance. Multiple factors including platelet activation are relevant to no-reflow. Calprotectin is found to be a biomarker of plaque instability and is identified to be a novel diagnostic and prognostic biomarker of cardiovascular diseases. The association of plasma calprotectin with platelet activation and no-reflow phenomenon in ACS is not clear. Methods In this prospective study performed at Yantai Yuhuangding Hospital from 2017 to 2018, a total of 176 Chinese patients with ACS who had undergone PCIs were recruited consecutively, aged from 30 to 88 years. Angiographic no-reflow was defined as thrombolysis in myocardial infarction grade less than 3. Blood samples were collected immediately at admission for the detection of plasma calprotectin and platelet–monocyte aggregates formation. Statistical analysis was performed for the variable’s comparisons between groups and the prediction value of plasma calprotectin for no-reflow. Results The mean age of the 176 included ACS patients were 64(±11) years and acute ST-segment elevation myocardial infarction (STEMI) was present in 41.5% of patients. Twenty-two patients had no-reflow during the PCI procedures and the prevalence was 12.5%. Patients with higher plasma calprotectin had a higher level of platelet–monocyte aggregates (PMA) and a higher prevalence of no-reflow (p < 0.001). The multivariate regression showed that plasma calprotectin and admission hs-cTnI were independently associated with PMA, while plasma calprotectin and serum LDL-c were independent predictors of no-reflow (p < 0.001 and p = 0.017). AUC of calprotectin for predicting no-reflow were 0.898. The cut-off value of plasma calprotectin for no-reflow was 4748.77 ng/mL with a sensitivity of 0.95 and a specificity of 0.77. Conclusion Plasma calprotectin was associated with platelet activation and may act as an early predictive biomarker of no-reflow in patients with acute coronary syndrome.http://link.springer.com/article/10.1186/s12872-020-01717-5CalprotectinPlatelet activationNo-reflowAcute coronary syndrome |
| spellingShingle | Nian-Peng Song Xiao-Wen Zhen Liu-dong Li Lin Zhong Hua Wang Yi An Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome BMC Cardiovascular Disorders Calprotectin Platelet activation No-reflow Acute coronary syndrome |
| title | Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome |
| title_full | Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome |
| title_fullStr | Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome |
| title_full_unstemmed | Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome |
| title_short | Plasma calprotectin was associated with platelet activation and no-reflow phenomenon in acute coronary syndrome |
| title_sort | plasma calprotectin was associated with platelet activation and no reflow phenomenon in acute coronary syndrome |
| topic | Calprotectin Platelet activation No-reflow Acute coronary syndrome |
| url | http://link.springer.com/article/10.1186/s12872-020-01717-5 |
| work_keys_str_mv | AT nianpengsong plasmacalprotectinwasassociatedwithplateletactivationandnoreflowphenomenoninacutecoronarysyndrome AT xiaowenzhen plasmacalprotectinwasassociatedwithplateletactivationandnoreflowphenomenoninacutecoronarysyndrome AT liudongli plasmacalprotectinwasassociatedwithplateletactivationandnoreflowphenomenoninacutecoronarysyndrome AT linzhong plasmacalprotectinwasassociatedwithplateletactivationandnoreflowphenomenoninacutecoronarysyndrome AT huawang plasmacalprotectinwasassociatedwithplateletactivationandnoreflowphenomenoninacutecoronarysyndrome AT yian plasmacalprotectinwasassociatedwithplateletactivationandnoreflowphenomenoninacutecoronarysyndrome |